$HTBX news, Heat Biologics to Present at Two Up
Post# of 22755
Posted On: 10/17/2016 7:49:37 AM
$HTBX news,
Heat Biologics to Present at Two Upcoming Investor Conferences and Panel Discussion
DURHAM, N.C., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq: HTBX ), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that Jeff Wolf, CEO of Heat is scheduled to present at the following investor conferences:
BIO Investor Forum
Date: Tuesday, October 18, 2016 Time: 3:30 PM Eastern Time Location: Westin St. Francis Hotel in San Francisco, CA Main Therapeutic Focus: Immunology Webcast: http://ir.heatbio.com/events-presentations . The webcast will be archived on the company’s website for a period of three months.
The Dawson James Growth Stock Conference
Date: Thursday, October 20, 2016 Time: 10:00 AM Eastern Time Location: Wyndham Grand Hotel in Jupiter, FL Webcast: http://ir.heatbio.com/events-presentations . The webcast will be archived on the company’s website for a period of three months.
Additionally, Chief Scientific Officer, Taylor Schreiber, M.D., Ph.D., will participate in a panel discussion on “The Sizzling Science and Business of Immuno-Oncology” at the North Carolina Biotechnology Center, on October 25th, from 4-7 PM. For more information on the panel please go to: http://www.ncbiotech.org/event/life-sciences-forum/191426 .
About Heat Biologics, Inc. Heat Biologics, Inc. (Nasdaq: HTBX ) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT , form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com .
CONTACT: For Investor Inquiries: David Waldman 919-240-7133 Investorrelations@heatbio.com For Media Inquiries: Deanne Eagle Planet Communications 917-837-5866 deanne@planetcommunications.nyc
Read More: http://investorshangout.com/post/view?id=4118...z4NLHokhcl
Heat Biologics to Present at Two Upcoming Investor Conferences and Panel Discussion
DURHAM, N.C., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq: HTBX ), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that Jeff Wolf, CEO of Heat is scheduled to present at the following investor conferences:
BIO Investor Forum
Date: Tuesday, October 18, 2016 Time: 3:30 PM Eastern Time Location: Westin St. Francis Hotel in San Francisco, CA Main Therapeutic Focus: Immunology Webcast: http://ir.heatbio.com/events-presentations . The webcast will be archived on the company’s website for a period of three months.
The Dawson James Growth Stock Conference
Date: Thursday, October 20, 2016 Time: 10:00 AM Eastern Time Location: Wyndham Grand Hotel in Jupiter, FL Webcast: http://ir.heatbio.com/events-presentations . The webcast will be archived on the company’s website for a period of three months.
Additionally, Chief Scientific Officer, Taylor Schreiber, M.D., Ph.D., will participate in a panel discussion on “The Sizzling Science and Business of Immuno-Oncology” at the North Carolina Biotechnology Center, on October 25th, from 4-7 PM. For more information on the panel please go to: http://www.ncbiotech.org/event/life-sciences-forum/191426 .
About Heat Biologics, Inc. Heat Biologics, Inc. (Nasdaq: HTBX ) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT , form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com .
CONTACT: For Investor Inquiries: David Waldman 919-240-7133 Investorrelations@heatbio.com For Media Inquiries: Deanne Eagle Planet Communications 917-837-5866 deanne@planetcommunications.nyc
Read More: http://investorshangout.com/post/view?id=4118...z4NLHokhcl
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼